MaxCyte, Inc. Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration
MaxCyte, Inc. (MXCT) had Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration of $29.50 million as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration · last filed 2026-03-25
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $29.50M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $32.70M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration |
|---|---|
| 2025-12-31 | $29.50M 10-K · filed 2026-03-25 |
| 2024-12-31 | $32.70M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |